CD40.SARS.CoV2 Vaccine Induces Long-Lasting T-Cell Immunity
Author Information
Author(s): Nguema Laury, Picard Florence, El Hajj Marwa, Dupaty Léa, Fenwick Craig, Cardinaud Sylvain, Wiedemann Aurélie, Pantaleo Giuseppe, Zurawski Sandra, Zurawski Gerard, Lévy Yves, Godot Véronique
Primary Institution: Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
Hypothesis
Can a CD40-targeting subunit vaccine induce long-lasting T-cell immunity against SARS-CoV-2?
Conclusion
The CD40.CoV2 vaccine effectively generates functional CD8+ T stem cell-like memory cells, providing long-lasting immunity against SARS-CoV-2.
Supporting Evidence
- The CD40.CoV2 vaccine selectively enriched long-lived CD8+ T stem cell-like memory cells.
- CD8+ T stem cell-like memory cells produced IFNγ and TNF upon antigenic restimulation.
- CD40 activation is specifically required for the generation of CD8+ T stem cell-like memory cells.
- The vaccine induced a significant frequency of RBD-specific T stem cell-like memory cells.
Takeaway
A new vaccine that targets a specific part of the immune system helps create strong and lasting defenses against COVID-19.
Methodology
The study used humanized mice to evaluate the immune response to the CD40.CoV2 vaccine, measuring T-cell responses and memory cell formation.
Limitations
The study was conducted in a single humanized mouse model and did not assess cytotoxic activity of CD8+ T cells.
Participant Demographics
Humanized mice reconstituted with human fetal liver hematopoietic stem cells from eight different HLA-A∗0201 donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website